Daewoong Pharmaceutical has started developing product to compete against Lily Korea’s JAK inhibitor 'Olumiant (baricitinib).'

Olumiant was approved by the Ministry of Food and Drug Safety (MFDS) in December 2017. It is used for treating adult patients with moderate-to-severe rheumatoid arthritis who do not respond well to disease-modifying antirheumatic drugs (DMARDs) and have no tolerability.

The patents for Olumiant 2/4 mg is registered until July 2032. Therefore, pharmaceutical companies in South Korea can only launch their generics after avoiding patent infringement.

On May 13, the MFDS approved clinical trials for Daewoong’s 'DWJ1607' and 'DWC202401' to con